Menu Search
Equities

Clinuvel Pharmaceuticals Ltd

CUV:ASX

Clinuvel Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)14.39
  • Today's Change-0.41 / -2.77%
  • Shares traded284.16k
  • 1 Year change-6.74%
  • Beta0.6552
Data delayed at least 20 minutes, as of Sep 20 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Clinuvel Pharmaceuticals Ltd grew revenues 16.15% from 82.23m to 95.50m while net income improved 16.44% from 30.60m to 35.64m.
Gross margin101.16%
Net profit margin37.31%
Operating margin58.53%
Return on assets16.78%
Return on equity19.39%
Return on investment19.05%
More ▼

Cash flow in AUDView more

In 2024, Clinuvel Pharmaceuticals Ltd increased its cash reserves by 10.37%, or 3.31m. The company earned 37.05m from its operations for a Cash Flow Margin of 38.80%. In addition the company used 29.03m on investing activities and also paid 3.57m in financing cash flows.
Cash flow per share0.7208
Price/Cash flow per share20.15
Book value per share4.05
Tangible book value per share4.05
More ▼

Balance sheet in AUDView more

Clinuvel Pharmaceuticals Ltd uses little debt in its capital structure as supported by a debt to capital ratio of 0.43%.
Current ratio8.81
Quick ratio8.39
Total debt/total equity0.0043
Total debt/total capital0.0043
More ▼

Growth rates in AUD

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 18.24%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)0.21%
Div growth rate (5 year)14.87%
Payout ratio (TTM)0.00%
EPS growth(5 years)13.82
EPS (TTM) vs
TTM 1 year ago		18.79
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.